Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study
Objective To compare the 1-year retention rate of secukinumab in axial spondyloarthritis (axSpA) and its predisposing factors with regard to its time of initiation (eg, right after or remotely from its launch).Methods Study design: Retrospective multicentre French study of patients with axSpA. Study...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-02-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/10/1/e003942.full |